Clinical trials: HIV Disease
HIV Infections
AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV
The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is in treating HIV-1 infected people who have failed treatment with lamivudine.
- Trial name
- NCT00126880
- Testing
- AVX754, 3TC
- Where
- Australia
- Volunteers
- 52 people
- Sponsor
- Avexa
Chronic Hepatitis C, Human Immunodeficiency Virus
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This is an Open-label Phase 3 study in adults with chronic genotypes 1, 2, 3, and 4 HCV infection who are co-infected with HIV-1.
- Trial name
- NCT01783678
- Testing
- Sofosbuvir, RBV
- Where
- 24 sites in Australia, France and 4 more
- Volunteers
- 275 people
- Sponsor
- Gilead Sciences
Mycoses, HIV Infections
A Study of Fluconazole in the Prevention of Fungal Infections in HIV-Infected Patients Living in Areas Where Fungal Infections Are Common
To compare the efficacy of fluconazole versus placebo in preventing the development of active coccidioidomycosis and other systemic fungal infections among HIV-infected patients with CD4 lymphocyte counts < 250 cells/mm3 who are…
- Conditions
- Mycoses, HIV Infections, Coccidioidomycosis
- Trial name
- NCT00002325
- Testing
- Fluconazole
- Where
- 3 sites in United States
- Sponsor
- Pfizer
HIV Infections
A Study of 1592U89 in HIV-Infected Children
The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available.
- Trial name
- NCT00002197
- Testing
- Abacavir sulfate
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Glaxo Wellcome
Meningitis, Cryptococcal, HIV Infections
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.
To evaluate and estimate the safety and efficacy of the combination of fluconazole and flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS.
- Trial name
- NCT00002113
- Testing
- Flucytosine, Fluconazole
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Pfizer
HIV Infections
A Study of DPC 817 in HIV-Infected Males
The purpose of this study is to evaluate DPC 817. The safety, dosages, and how the body responds to the drug will be studied.
- Trial name
- NCT00040274
- Testing
- DPC 817
- Where
- 2 sites in United States, Germany
- Volunteers
- 30 people
- Sponsor
- Pharmasset
HIV Infection
Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe
The purpose of this study is to monitor adverse events in HIV-infected children <18 years old who are exposed to Atazanavir in a real-world setting in Europe.
- Trial name
- NCT01389310
- Where
- 9 sites in Belgium, Germany and 5 more
- Volunteers
- 249 people
- Sponsor
- Bristol-Myers Squibb
Acquired Immunodeficiency Syndrome
Dimiracetam in Painful Neuropathies Affecting AIDS Patients
The purpose of this study is to assess the efficacy and tolerability of orally administered dimiracetam for 10 weeks to AIDS patients under treatment with antiretroviral agents presenting a disease and /or treatment related…
- Trial name
- DIPANAP (NCT01444690)
- Testing
- Dimiracetam, Dimiracetam 25 mg
- Where
- Switzerland
- Volunteers
- 244 people
- Sponsor
- Neurotune AG
Infection, Human Immunodeficiency Virus
Evaluation of the Bioequivalence of a Combined Formulated Tablet
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01622790
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
A single oral dose study in subjects with hepatic impairment and healthy control subjects. Subjects will stay at the clinical facility where interval blood samplings will be obtained and examined for drug effect.
- Trial name
- NCT02467335
- Testing
- BMS-663068
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
This is an open-label, dose-escalation study to investigate the safety, tolerability and pharmacokinetics (PK) of single subcutaneous (SC) administration of long acting (LA) Cabotegravir (CAB) 200 milligrams per milliliter…
- Trial name
- NCT05418868
- Testing
- Cabotegravir 200 mg/mL, Cabotegravir >=400 mg/mL, Cabotegravir Formulation I
- Where
- 3 sites in United States
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, Acquired Immune Deficiency Syndrome
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients
The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.
- Trial name
- NCT00055185
- Testing
- CD4-IgG2 (PRO 542)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
HIV Infections
A Safety Study to Assess the Delivery of Dapivirine From a Matrix Vaginal Ring
The proposed study is a single-center, double-blind, randomised, placebo-controlled trial to evaluate the delivery of dapivirine from matrix vaginal rings over a 56 and 57 day period and to assess the safety as compared to…
- Trial name
- NCT01144676
- Testing
- dapivirine
- Where
- Belgium
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV, AIDS
TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.
This is a Phase I, open-label, 3-period crossover trial to investigate the pharmacokinetic interaction (process by which a drug is absorbed, distributed, metabolised and eliminated by the body) between TMC125 and fluconazole, and…
- Conditions
- HIV, AIDS, Fungal Infection
- Trial name
- NCT00740389
- Testing
- TMC125
- Volunteers
- 18 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.
- Trial name
- NCT00002217
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir
- Where
- United States
- Sponsor
- Glaxo Wellcome
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
The goal of this clinical study is to learn more about the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme [CYP]3A inhibitor), voriconazole (VOR)…
- Trial name
- NCT05458102
- Testing
- Vesatolimod, Cobicistat, Voriconazole
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Tuberculosis
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.
This study will assess the safety and immunogenicity of a GSK Biologicals' candidate TB vaccine (692342) administered at 0, 1 month to HIV-positive adults living in Switzerland.
- Trial name
- NCT00707967
- Testing
- GSK's candidate Mycobacterium tuberculosis vaccine 692342, Control vaccine with the adjuvant system., Control vaccine with physiological saline
- Where
- Switzerland
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
HIV Infections
A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection
To determine the safety and pharmacokinetics of L-ofloxacin (RWJ 25213) in patients with HIV infection.
- Trial name
- NCT00002249
- Testing
- Levofloxacin
- Where
- United States
- Sponsor
- R W Johnson Pharmaceutical Research Institute
Influenza
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment…
- Trial name
- PO206 (NCT00979251)
- Testing
- Oseltamivir Phosphate, ADS-8902
- Where
- 25 sites in United States, Australia and 3 more
- Volunteers
- 2 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
HIV Infections
A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications
The purpose of this study is to see if it is safe and effective to give the protease inhibitor (PI) amprenavir (APV) to patients with fat production and distribution problems associated with other PIs.
- Trial name
- NCT00002417
- Testing
- Amprenavir
- Where
- United States
- Sponsor
- Glaxo Wellcome
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.